Want to see CH:SANN full AI Analyst Report?

Santhera Pharmaceuticals Holding (SANN) Price & Analysis

5 Followers

SANN Stock Chart & Stats

CHF17.62

-CHF0.14(-0.88%)

At close: Mar 06 4:00 PM EST

CHF17.62

-CHF0.14(-0.88%)

Day’s Range― - ―

52-Week RangeCHF9.38 - CHF18.84

Previous CloseN/A

Volume24.19K

Average Volume (3M)55.85K

Market Cap

CHF232.91M

Enterprise ValueCHF302.54M

Total Cash (Recent Filing)CHF22.44M

Total Debt (Recent Filing)CHF97.77M

Price to Earnings (P/E)―

Beta1.00

Next Earnings

Sep 21, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.82

Shares Outstanding15,456,525

10 Day Avg. Volume57,231

30 Day Avg. Volume55,851

Financial Highlights & Ratios

PEG Ratio-1.37

Price to Book (P/B)-13.88

Price to Sales (P/S)2.12

P/FCF Ratio-4.71

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF30.00

Price Target Upside70.26% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.6

Revenue Forecast (FY)CHF96.35M

Bulls Say, Bears Say

Bulls Say

Approved Rare-disease ProductOwning an approved, disease-specific therapy creates a durable commercial foundation: AGAMREE targets a small, high-need DMD population where reimbursement and pricing can be favorable. This focused product reduces commercial complexity and supports recurring product revenues and partner interest.

Strong 2025 Revenue ReboundA large, recent revenue rebound demonstrates the company can scale sales and achieve market uptake for AGAMREE. Sustained top-line growth provides a path to leverage fixed costs, improve operating leverage and supports future margin recovery if cash burn and investment levels are controlled.

Partnering / Monetization ModelAn explicit strategy to monetize rights via licensing and partnerships reduces capital intensity and concentrates risk with experienced commercialization partners. This asset-light approach preserves flexibility, enables geographic expansion without full build-out, and can generate milestone/royalty streams.

Bears Say

Weakened Balance SheetNegative equity and a sharp increase in debt materially reduce financial flexibility and raise refinancing risk. With limited reserves, the company may face constrained ability to fund launches, invest in trials, or negotiate favourable partner terms absent new capital or asset sales.

Persistent Cash BurnConsistent negative operating and free cash flow imply the business is not yet self-funding. Ongoing cash burn forces reliance on external financing or partner upfronts, which can dilute shareholders, increase leverage, and limit the company's ability to invest in commercialization or pipeline advancement.

Volatile And Returned-to-loss EarningsEarnings volatility undermines predictability of margins and free cash generation. A swing from prior profitability to substantial losses signals unstable cost structure or one-time items and reduces visibility on sustainable margins, complicating long-term planning and partner negotiations.

Santhera Pharmaceuticals Holding News

Santhera: Buy Rating Reiterated as AGAMREE Traction and Governance Stability Support Unchanged CHF30 Price Target

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Santhera Pharmaceuticals Holding today and set a price...

1M ago

Analyst Reiterates Buy on Santhera, Citing Leadership Transition and AGAMREE Momentum with Unchanged $30 Price Target

Santhera Pharmaceuticals Holding, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

2M ago

Santhera: Advancing AGAMREE Reimbursement and European Uptake Underpins Reiterated Buy and CHF30 Target

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Santhera Pharmaceuticals Holding. The associated price...

3M ago

Santhera Pharmaceuticals Advances Vamorolone Study for Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag (($SPHDF)) announced an update on their ongoing clinical study. Santhera Pharmaceuticals is conducting a...

8M ago

SPHDF

Santhera’s Earnings Call: Positive Outlook Amid Challenges

Santhera Pharmaceuticals Holding Ag (($CH:SANN)) has held its Q2 earnings call. Read on for the main highlights of...

9M ago

Santhera Pharmaceuticals Reports Strong H1 2025 Growth

Santhera Pharmaceuticals Holding Ag ( ($SPHDF) ) has released its Q2 earnings. Here is a breakdown of the...

9M ago

Santhera price target raised to CHF 30 from CHF 25 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals (SPHDF) to CHF 30 from CHF 25 and...

1y ago

Santhera Pharmaceuticals: Buy Rating Affirmed on Strong Commercial Traction and Promising Financial Outlook

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Santhera Pharmaceuticals Holding (SPHDF – Research Report) today...

1y ago

Santhera Pharmaceuticals: Transformative Year with AGAMREE Success

Santhera Pharmaceuticals Holding Ag ( ($SPHDF) ) has released its Q4 earnings. Here is a breakdown of the...

1y ago

Santhera Pharmaceuticals: Buy Rating Affirmed on Strategic Milestones and Growth Prospects

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Santhera Pharmaceuticals Holding...

1y ago

Santhera price target lowered to CHF 25 from CHF 30 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Santhera Pharmaceuticals to CHF 25 from CHF 30 and keeps...

2y ago

Santhera price target raised to CHF 28 from CHF 24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals to CHF 28 from CHF 24 and keeps...

3y ago

SANN FAQ

What was Santhera Pharmaceuticals Holding’s price range in the past 12 months?

Santhera Pharmaceuticals Holding lowest stock price was CHF9.38 and its highest was CHF18.84 in the past 12 months.

What is Santhera Pharmaceuticals Holding’s market cap?

Santhera Pharmaceuticals Holding’s market cap is CHF232.91M.

When is Santhera Pharmaceuticals Holding’s upcoming earnings report date?

Santhera Pharmaceuticals Holding’s upcoming earnings report date is Sep 21, 2026 which is in 81 days.

How were Santhera Pharmaceuticals Holding’s earnings last quarter?

Santhera Pharmaceuticals Holding released its earnings results on Apr 28, 2026. The company reported -CHF0.43 earnings per share for the quarter, the consensus estimate of -CHF0.43 by CHF0.

Is Santhera Pharmaceuticals Holding overvalued?

According to Wall Street analysts Santhera Pharmaceuticals Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Santhera Pharmaceuticals Holding pay dividends?

Santhera Pharmaceuticals Holding does not currently pay dividends.

What is Santhera Pharmaceuticals Holding’s EPS estimate?

Santhera Pharmaceuticals Holding’s EPS estimate is -0.09.

How many shares outstanding does Santhera Pharmaceuticals Holding have?

Santhera Pharmaceuticals Holding has 15,456,525 shares outstanding.

What happened to Santhera Pharmaceuticals Holding’s price movement after its last earnings report?

Santhera Pharmaceuticals Holding reported an EPS of -CHF0.43 in its last earnings report, expectations of -CHF0.43. Following the earnings report the stock price went up 0.98%.

Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding?

Currently, no hedge funds are holding shares in CH:SANN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Santhera Pharmaceuticals Holding

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Santhera Pharmaceuticals Holding (SANN) Earnings & Revenues

Historic Earnings Reports

SANN Company Deck

SANN Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.View all CH:SANN earnings summaries

SANN Stock 12 Month Forecast

Average Price Target

CHF30.00

▲(70.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"CHF9","20":"CHF20","31":"CHF31","14.5":"CHF14.5","25.5":"CHF25.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,14.5,20,25.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.8,16.892307692307693,17.984615384615385,19.076923076923077,20.16923076923077,21.26153846153846,22.353846153846156,23.446153846153848,24.53846153846154,25.630769230769232,26.723076923076924,27.815384615384616,28.907692307692308,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.8,16.892307692307693,17.984615384615385,19.076923076923077,20.16923076923077,21.26153846153846,22.353846153846156,23.446153846153848,24.53846153846154,25.630769230769232,26.723076923076924,27.815384615384616,28.907692307692308,{"y":30,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.8,16.892307692307693,17.984615384615385,19.076923076923077,20.16923076923077,21.26153846153846,22.353846153846156,23.446153846153848,24.53846153846154,25.630769230769232,26.723076923076924,27.815384615384616,28.907692307692308,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >